Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China
作者全名："Leung, Kam Tong; Cai, Jiaoyang; Liu, Yu; Chan, Kathy Yuen Yee; Shao, Jingbo; Yang, Hui; Hu, Qun; Xue, Yao; Wu, Xuedong; Guo, Xia; Zhai, Xiaowen; Wang, Ningling; Li, Xue; Tian, Xin; Li, Zheng; Xue, Ning; Guo, Yuxia; Wang, Lingzhen; Zou, Yao; Xiao, Peifang; He, Yingyi; Jin, Runming; Tang, Jingyan; Yang, Jun J.; Shen, Shuhong; Pui, Ching-Hon; Li, Chi Kong"
作者地址："[Leung, Kam Tong; Chan, Kathy Yuen Yee; Li, Chi Kong] Chinese Univ Hong Kong, Dept Paediat, Shatin, Hong Kong, Peoples R China; [Leung, Kam Tong; Li, Chi Kong] Chinese Univ Hong Kong, Hong Kong Hub Paediat Excellence, Shatin, Hong Kong, Peoples R China; [Cai, Jiaoyang; Tang, Jingyan; Shen, Shuhong] Shanghai Jiao Tong Univ, Natl Hlth Comm, Shanghai Childrens Med Ctr, Dept Hematol Oncol,Sch Med,Key Lab Pediat Hematol, Shanghai, Peoples R China; [Liu, Yu] Shanghai Jiao Tong Univ, Natl Hlth Comm, Pediat Translat Med Inst, Shanghai Childrens Med Ctr,Sch Med,Key Lab Pediat, Shanghai, Peoples R China; [Shao, Jingbo] Shanghai Jiao Tong Univ, Shanghai Childrens Hosp, Dept Hematol & Oncol, Shanghai, Peoples R China; [Yang, Hui] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Peoples R China; [Hu, Qun] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China; [Xue, Yao] Nanjing Med Univ, Dept Hematol & Oncol, Childrens Hosp, Nanjing, Peoples R China; [Wu, Xuedong] Southern Med Univ, Nanfang Hosp, Dept Pediat, Guangzhou, Peoples R China; [Guo, Xia] Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Childr, Minist Educ,Dept Pediat, Chengdu, Peoples R China; [Zhai, Xiaowen] Fudan Univ, Dept Hematol & Oncol, Childrens Hosp, Shanghai, Peoples R China; [Wang, Ningling] Anhui Med Univ, Affiliated Hosp 2, Dept Pediat, Hefei, Anhui, Peoples R China; [Li, Xue] Shandong Univ, Qilu Hosp, Dept Pediat, Jinan, Peoples R China; [Tian, Xin] Kunming Childrens Hosp, Dept Hematol & Oncol, Kunming, Peoples R China; [Li, Zheng] Jiangxi Prov Childrens Hosp, Dept Hematol Oncol, Nanchang, Peoples R China; [Xue, Ning] Xian Northwest Womens & Childrens Hosp, Dept Hematol Oncol, Xian, Peoples R China; [Guo, Yuxia] Chongqing Med Univ, Affiliated Childrens Hosp, Dept Hematol Oncol, Chongqing, Peoples R China; [Wang, Lingzhen] Qingdao Univ, Dept Pediat, Affiliated Hosp, Qingdao, Peoples R China; [Zou, Yao] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol,Dept Pediat, Tianjin, Peoples R China; [Zou, Yao] Blood Dis Hosp, Chinese Acad Med Sci & Peking Union Med Coll, Tianjin, Peoples R China; [Xiao, Peifang] Soochow Univ, Childrens Hosp, Dept Hematol & Oncol, Suzhou, Peoples R China; [He, Yingyi] Guangzhou Women & Childrens Med Ctr, Dept Hematol Oncol, Guangzhou, Peoples R China; [Jin, Runming] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China; [Yang, Jun J.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Global Pediat Med, Memphis, TN 38105 USA"
通信作者："Li, CK (通讯作者)，Chinese Univ Hong Kong, Dept Paediat, Shatin, Hong Kong, Peoples R China.; Li, CK (通讯作者)，Chinese Univ Hong Kong, Hong Kong Hub Paediat Excellence, Shatin, Hong Kong, Peoples R China.; Shen, SH (通讯作者)，Shanghai Jiao Tong Univ, Natl Hlth Comm, Shanghai Childrens Med Ctr, Dept Hematol Oncol,Sch Med,Key Lab Pediat Hematol, Shanghai, Peoples R China.; Pui, CH (通讯作者)，St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.; Pui, CH (通讯作者)，St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA.; Pui, CH (通讯作者)，St Jude Childrens Res Hosp, Dept Global Pediat Med, Memphis, TN 38105 USA."
来源：LEUKEMIA
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:001114047400001
JCR分区：Q1
影响因子：12.8
年份：2024
卷号：38
期号：2
开始页：250
结束页：257
文献类型：Article; Early Access
关键词：
摘要："The outcomes of children with acute lymphoblastic leukemia (ALL) have been incrementally improved with risk-directed chemotherapy but therapy responses remain heterogeneous. Parameters with added prognostic values are warranted to refine the current risk stratification system and inform appropriate therapies. CD9, implicated by our prior single-center study, holds promise as one such parameter. To determine its precise prognostic significance, we analyzed a nationwide, multicenter, uniformly treated cohort of childhood ALL cases, where CD9 status was defined by flow cytometry on diagnostic samples of 3781 subjects. CD9 was expressed in 88.5% of B-ALL and 27.9% of T-ALL cases. It conferred a lower 5-year EFS and a higher CIR in B-ALL but not in T-ALL patients. The prognostic impact of CD9 was most pronounced in the intermediate/high-risk arms and those with minimal residual diseases, particularly at day 19 of remission induction. The adverse impact of CD9 was confined to specific cytogenetics, notably BCR::ABL1+ rather than KMT2A-rearranged leukemia. Multivariate analyses confirmed CD9 as an independent predictor of both events and relapse. The measurement of CD9 offers insights into patients necessitating intervention, warranting its seamless integration into the diagnostic marker panel to inform risk level and timely introduction of therapeutic intervention for childhood ALL."
基金机构："Children's Cancer Foundation; VIVA China Children's Cancer Foundation [GRF-14108615, ECS-24121922]; Children's Cancer Foundation, Hong Kong [HMRF-PR-CUHK-1]; Research Grants Council, Hong Kong; Health Bureau, Hong Kong; American Lebanese Syrian Associated Charities (ALSAC)"
基金资助正文："This study was supported by the VIVA China Children's Cancer Foundation and Children's Cancer Foundation, Hong Kong; and by grants GRF-14108615 and ECS-24121922 from the Research Grants Council, Hong Kong; and HMRF-PR-CUHK-1 from the Health Bureau, Hong Kong; and the American Lebanese Syrian Associated Charities (ALSAC). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors are grateful to the families who consented to take part in the study and to all clinical/research staff of the participating centers who contributed to patient management and data collection."
